SCHEDULE: Topline Capital Discloses 5.6% Stake in Nephros Inc.

Topline Capital Management, LLC, Collin McBirney, and Topline Capital Partners, LP have disclosed a 5.6% beneficial ownership stake in Nephros Inc. common stock.

Summary

• Topline Capital Management, LLC, Collin McBirney, and Topline Capital Partners, LP (the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Nephros Inc.
• The Reporting Persons collectively beneficially own 595,334 shares of Nephros Inc. common stock.
• This ownership represents 5.6% of the outstanding shares of Nephros Inc., based on 10,626,683 shares outstanding as of November 3, 2025.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Nephros Inc.
• Topline Capital Management, LLC, as the investment manager and general partner of Topline Capital Partners, LP, and Collin McBirney, as the member-manager of Topline Capital Management, LLC, may be deemed to beneficially own the securities.
• The Reporting Persons expressly disclaim beneficial ownership as to the securities held by the Fund, except to the extent of their pecuniary interests therein.

Sentiment

Score: 6

Explanation: The disclosure of a new 5.6% beneficial ownership stake by an institutional investor is generally a neutral to slightly positive signal, indicating investor interest without implying any immediate operational changes or financial performance.

Positives

• A significant institutional investor, Topline Capital, has taken a 5.6% stake in Nephros Inc., which can be interpreted as a signal of confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, potentially long-term investment approach.

Risks

• The filing itself does not detail operational or financial risks related to Nephros Inc. It includes standard legal disclaimers regarding beneficial ownership, stating that the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interests.

Future Outlook

Not applicable as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Management Comments

• "The securities reported on this Schedule as beneficially owned by TCM (the 'Securities') are held by and for the benefit of the Fund."
• "Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of TCM or Mr. McBirney is, for any other purpose, the beneficial owner of any of the Securities held by the Fund, and each of TCM and Mr. McBirney expressly disclaims beneficial ownership as to the Securities held by the Fund, except to the extent of its or his pecuniary interests therein."

Industry Context

This filing is a standard disclosure of a significant ownership stake by an investment firm. It does not provide specific industry context or relate to broader industry trends, but rather indicates an investment decision by Topline Capital in Nephros Inc.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
• Management: Awareness of a new 5.6% shareholder, though passive, could influence strategic considerations.

Key Dates

Recommendation

The filing indicates a new significant beneficial ownership stake by Topline Capital, which is a neutral to slightly positive development as it signals institutional interest. However, a Schedule 13G filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further company-specific financial disclosures or strategic updates to make a more informed decision, while acknowledging the positive signal of institutional investment.

Keywords

Nephros Inc., Topline Capital Management, Collin McBirney, Topline Capital Partners, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Stake